Published in J Neuropathol Exp Neurol on May 01, 2013
Immunohistochemical expression of IMP3 and p53 in inflammatory lesions and neoplastic lesions of the gastric mucosa. Int J Clin Exp Pathol (2014) 0.79
Pilomyxoid Astrocytoma (PMA) Shows Significant Differences in Gene Expression vs. Pilocytic Astrocytoma (PA) and Variable Tendency Toward Maturation to PA. Brain Pathol (2015) 0.79
The oncofetal protein IMP3: a novel grading tool and predictor of poor clinical outcome in human gliomas. Biomed Res Int (2015) 0.77
Expression of the cancer testis antigen IGF2BP3 in colorectal cancers; IGF2BP3 holds promise as a specific immunotherapy target. Oncoscience (2015) 0.76
The expression of Wnt-1 inducible signaling pathway protein-2 in astrocytoma: Correlation between pathological grade and clinical outcome. Oncol Lett (2014) 0.75
IGF2BP3 as a potential tissue marker for the diagnosis of esophageal high-grade intraepithelial neoplasia. Onco Targets Ther (2017) 0.75
Prognostic value of high IMP3 expression in solid tumors: a meta-analysis. Onco Targets Ther (2017) 0.75
Gene ontology: tool for the unification of biology. The Gene Ontology Consortium. Nat Genet (2000) 336.52
A family of insulin-like growth factor II mRNA-binding proteins represses translation in late development. Mol Cell Biol (1999) 5.58
BRAF gene duplication constitutes a mechanism of MAPK pathway activation in low-grade astrocytomas. J Clin Invest (2008) 3.98
Analysis of BRAF V600E mutation in 1,320 nervous system tumors reveals high mutation frequencies in pleomorphic xanthoastrocytoma, ganglioglioma and extra-cerebellar pilocytic astrocytoma. Acta Neuropathol (2011) 3.66
Activation of the ERK/MAPK pathway: a signature genetic defect in posterior fossa pilocytic astrocytomas. J Pathol (2009) 3.32
Duplication of 7q34 in pediatric low-grade astrocytomas detected by high-density single-nucleotide polymorphism-based genotype arrays results in a novel BRAF fusion gene. Brain Pathol (2008) 2.61
Cloning of a gene highly overexpressed in cancer coding for a novel KH-domain containing protein. Oncogene (1997) 2.58
RNA-binding IMPs promote cell adhesion and invadopodia formation. EMBO J (2006) 2.34
Oncogenic RAF1 rearrangement and a novel BRAF mutation as alternatives to KIAA1549:BRAF fusion in activating the MAPK pathway in pilocytic astrocytoma. Oncogene (2009) 2.26
Low-grade astrocytoma: a decade of experience at St. Jude Children's Research Hospital. J Clin Oncol (1997) 1.94
Analysis of RNA-binding protein IMP3 to predict metastasis and prognosis of renal-cell carcinoma: a retrospective study. Lancet Oncol (2006) 1.61
A family of IGF-II mRNA binding proteins (IMP) involved in RNA trafficking. Scand J Clin Lab Invest Suppl (2001) 1.61
H19 RNA binds four molecules of insulin-like growth factor II mRNA-binding protein. J Biol Chem (2000) 1.54
Insulin growth factor-2 binding protein 3 (IGF2BP3) is a glioblastoma-specific marker that activates phosphatidylinositol 3-kinase/mitogen-activated protein kinase (PI3K/MAPK) pathways by modulating IGF-2. J Biol Chem (2011) 1.46
External validation of IMP3 expression as an independent prognostic marker for metastatic progression and death for patients with clear cell renal cell carcinoma. Cancer (2008) 1.45
Phase I/II trial and pharmacokinetic study of cixutumumab in pediatric patients with refractory solid tumors and Ewing sarcoma: a report from the Children's Oncology Group. J Clin Oncol (2011) 1.45
IGF2BP3 (IMP3) expression is a marker of unfavorable prognosis in ovarian carcinoma of clear cell subtype. Mod Pathol (2009) 1.33
IMP3 is a novel prognostic marker that correlates with colon cancer progression and pathogenesis. Ann Surg Oncol (2009) 1.29
The oncofetal protein IMP3: a novel biomarker for endometrial serous carcinoma. Am J Surg Pathol (2008) 1.26
Insulin-like growth factor 2 mRNA binding protein 3 (IGF2BP3) overexpression in pancreatic ductal adenocarcinoma correlates with poor survival. BMC Cancer (2010) 1.22
Long-term follow-up of the multicenter, multidisciplinary treatment study HIT-LGG-1996 for low-grade glioma in children and adolescents of the German Speaking Society of Pediatric Oncology and Hematology. Neuro Oncol (2012) 1.14
Anaplasia in pilocytic astrocytoma predicts aggressive behavior. Am J Surg Pathol (2010) 1.13
Regulation of IMP3 by EGFR signaling and repression by ERβ: implications for triple-negative breast cancer. Oncogene (2012) 1.08
Histopathologic predictors of pilocytic astrocytoma event-free survival. Acta Neuropathol (2009) 1.08
Cell cycle and aging, morphogenesis, and response to stimuli genes are individualized biomarkers of glioblastoma progression and survival. BMC Med Genomics (2011) 1.04
IMP3 expression in lesions of the biliary tract: a marker for high-grade dysplasia and an independent prognostic factor in bile duct carcinomas. Hum Pathol (2009) 1.02
Unique molecular characteristics of radiation-induced glioblastoma. J Neuropathol Exp Neurol (2007) 1.02
Gene expression profiling of NF-1-associated and sporadic pilocytic astrocytoma identifies aldehyde dehydrogenase 1 family member L1 (ALDH1L1) as an underexpressed candidate biomarker in aggressive subtypes. J Neuropathol Exp Neurol (2008) 1.00
Ki-67: a prognostic factor for low-grade glioma? Int J Radiat Oncol Biol Phys (2002) 0.96
Pharmacokinetically guided phase 1 trial of the IGF-1 receptor antagonist RG1507 in children with recurrent or refractory solid tumors. Clin Cancer Res (2010) 0.96
Study of the MIB-1 labeling index as a predictor of tumor progression in pilocytic astrocytomas in children and adolescents. J Clin Oncol (2003) 0.96
Biological effects induced by insulin-like growth factor binding protein 3 (IGFBP-3) in malignant melanoma. Int J Cancer (2010) 0.93
IMP3 expression in non-small cell lung cancer. Hum Pathol (2009) 0.90
Impact of morphology, MIB-1, p53 and MGMT on outcome in pilocytic astrocytomas. Brain Pathol (2009) 0.88
Pathologic characteristics of pediatric intracranial pilocytic astrocytomas and their impact on outcome in 3 countries: a multi-institutional study. Am J Surg Pathol (2012) 0.87
Proliferative and metabolic markers in incompletely excised pediatric pilocytic astrocytomas--an assessment of 3 new variables in predicting clinical outcome. Neuro Oncol (2011) 0.85
Cyclin D1 and MIB-1 immunohistochemistry in pilocytic astrocytomas: a study of 48 cases. Hum Pathol (1998) 0.84
Hotspot mutations in H3F3A and IDH1 define distinct epigenetic and biological subgroups of glioblastoma. Cancer Cell (2012) 6.71
Varicella zoster virus ischemic optic neuropathy and subclinical temporal artery involvement. Arch Neurol (2011) 2.82
Survey of MicroRNA expression in pediatric brain tumors. Pediatr Blood Cancer (2010) 1.82
Truncation in CCND1 mRNA alters miR-16-1 regulation in mantle cell lymphoma. Blood (2008) 1.71
Inhibition of Mer and Axl receptor tyrosine kinases in astrocytoma cells leads to increased apoptosis and improved chemosensitivity. Mol Cancer Ther (2010) 1.69
Surgical neuropathology update: a review of changes introduced by the WHO classification of tumours of the central nervous system, 4th edition. Arch Pathol Lab Med (2008) 1.61
Clinical metagenomic identification of Balamuthia mandrillaris encephalitis and assembly of the draft genome: the continuing case for reference genome sequencing. Genome Med (2015) 1.60
Pediatric brainstem gangliogliomas show overexpression of neuropeptide prepronociceptin (PNOC) by microarray and immunohistochemistry. Pediatr Blood Cancer (2012) 1.57
Vancomycin disposition and penetration into ventricular fluid of the central nervous system following intravenous therapy in patients with cerebrospinal devices. Pediatr Neurosurg (2007) 1.54
Diffuse intrinsic pontine tumors: a study of primitive neuroectodermal tumors versus the more common diffuse intrinsic pontine gliomas. J Neurosurg Pediatr (2012) 1.50
Patterns of care for craniopharyngioma: survey of members of the american association of neurological surgeons. Pediatr Neurosurg (2014) 1.41
Comparison of outcomes following decompressive craniectomy in children with accidental and nonaccidental blunt cranial trauma. J Neurosurg Pediatr (2012) 1.40
Tumor vaccination for malignant brain tumors. Pediatr Blood Cancer (2010) 1.38
MGMT promoter methylation correlates with survival benefit and sensitivity to temozolomide in pediatric glioblastoma. Pediatr Blood Cancer (2007) 1.37
Systemic distribution of West Nile virus infection: postmortem immunohistochemical study of six cases. Brain Pathol (2007) 1.30
Molecular characterization of human meningiomas by gene expression profiling using high-density oligonucleotide microarrays. Am J Pathol (2002) 1.29
The protean manifestations of varicella-zoster virus vasculopathy. J Neurovirol (2002) 1.28
Epithelioid GBMs show a high percentage of BRAF V600E mutation. Am J Surg Pathol (2013) 1.23
Fast multislice mapping of the myelin water fraction using multicompartment analysis of T2* decay at 3T: a preliminary postmortem study. Magn Reson Med (2007) 1.17
Inhibition of Aurora Kinase A enhances chemosensitivity of medulloblastoma cell lines. Pediatr Blood Cancer (2010) 1.15
Her-2/neu status in breast cancer metastases to the central nervous system. Arch Pathol Lab Med (2003) 1.11
Cerebral cavernous malformations: somatic mutations in vascular endothelial cells. Neurosurgery (2009) 1.10
Polo-like kinase 1 (PLK1) inhibition suppresses cell growth and enhances radiation sensitivity in medulloblastoma cells. BMC Cancer (2012) 1.10
Inhibition of EZH2 suppresses self-renewal and induces radiation sensitivity in atypical rhabdoid teratoid tumor cells. Neuro Oncol (2012) 1.09
Immune gene and cell enrichment is associated with a good prognosis in ependymoma. J Immunol (2009) 1.09
Bevacizumab as therapy for radiation necrosis in four children with pontine gliomas. Int J Radiat Oncol Biol Phys (2009) 1.06
PARP1 expression in pediatric central nervous system tumors. Pediatr Blood Cancer (2009) 1.04
Inhibition of BRD4 attenuates tumor cell self-renewal and suppresses stem cell signaling in MYC driven medulloblastoma. Oncotarget (2014) 1.02
Unique molecular characteristics of radiation-induced glioblastoma. J Neuropathol Exp Neurol (2007) 1.02
Targeting the enhancer of zeste homologue 2 in medulloblastoma. Int J Cancer (2012) 1.01
Molecular sub-group-specific immunophenotypic changes are associated with outcome in recurrent posterior fossa ependymoma. Acta Neuropathol (2013) 1.01
High expression of BMP pathway genes distinguishes a subset of atypical teratoid/rhabdoid tumors associated with shorter survival. Neuro Oncol (2011) 1.00
Claudin 6 is a positive marker for atypical teratoid/rhabdoid tumors. Brain Pathol (2009) 0.98
Reprimo (RPRM) is a novel tumor suppressor in pituitary tumors and regulates survival, proliferation, and tumorigenicity. Endocrinology (2012) 0.98
Murine gammaherpesvirus 68 infection of IFNgamma unresponsive mice: a small animal model for gammaherpesvirus-associated B-cell lymphoproliferative disease. Cancer Res (2009) 0.98
Pilomyxoid astrocytoma: neuroimaging with clinicopathologic correlates in 4 cases followed over time. J Pediatr Hematol Oncol (2007) 0.98
Epithelioid versus rhabdoid glioblastomas are distinguished by monosomy 22 and immunohistochemical expression of INI-1 but not claudin 6. Am J Surg Pathol (2010) 0.96
MicroRNA 218 acts as a tumor suppressor by targeting multiple cancer phenotype-associated genes in medulloblastoma. J Biol Chem (2012) 0.96
Epidermal growth factor receptor status in breast cancer metastases to the central nervous system. Comparison with HER-2/neu status. Arch Pathol Lab Med (2004) 0.95
A role for chromosome 9p21 deletions in the malignant progression of meningiomas and the prognosis of anaplastic meningiomas. Brain Pathol (2002) 0.95
Increased immune gene expression and immune cell infiltration in high-grade astrocytoma distinguish long-term from short-term survivors. J Immunol (2012) 0.95
Interobserver and intraobserver reproducibility in focal cortical dysplasia (malformations of cortical development). Epilepsia (2009) 0.95
Inhibition of cyclin-dependent kinase 6 suppresses cell proliferation and enhances radiation sensitivity in medulloblastoma cells. J Neurooncol (2012) 0.93
Characterization of distinct immunophenotypes across pediatric brain tumor types. J Immunol (2013) 0.92
Unique molecular characteristics of pediatric myxopapillary ependymoma. Brain Pathol (2009) 0.92
Aurora kinase A as a rational target for therapy in glioblastoma. J Neurosurg Pediatr (2010) 0.92
Paired overexpression of ErbB3 and Sox10 in pilocytic astrocytoma. J Neuropathol Exp Neurol (2006) 0.91
Integrated genomic analysis identifies the mitotic checkpoint kinase WEE1 as a novel therapeutic target in medulloblastoma. Mol Cancer (2014) 0.91
Variations in structural protein expression and endothelial cell proliferation in relation to clinical manifestations of cerebral cavernous malformations. Neurosurgery (2005) 0.91
Conventional MRI at presentation does not predict clinical response to radiation therapy in children with diffuse pontine glioma. Pediatr Radiol (2009) 0.91
Histone deacetylase inhibition decreases proliferation and potentiates the effect of ionizing radiation in atypical teratoid/rhabdoid tumor cells. Neuro Oncol (2011) 0.91